How Banks Underwrite Medical Spa Startups in 2026

We are seeing a significant shift in how lenders approach medical spa financing as we move through 2026. In previous years, banks relied heavily on the resale value of laser platforms as collateral, but modern underwriting now prioritizes the stability of membership-based recurring revenue. When we prepare files for traditional SBA 7(a) loans today, we focus on demonstrating a clear path to debt service coverage through tiered subscription models rather than one-off injectable sales. Lenders are particularly scrutinizing the contractual relationship between the business entity and the Medical Director, often requiring long-term management services agreements to mitigate the risk of clinical turnover. We have found that providing a detailed breakdown of patient acquisition costs versus lifetime value is now a non-negotiable requirement for securing competitive interest rates. To win at the closing table, we must prove that the practice can sustain operational overhead even if the primary injector departs, ensuring the business remains a viable cash-flowing asset.